Drugs / S095035
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06188702 | Apr 2024 → May 2027 expected | — | Servier Bio-Innovation LLC | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S095035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06188702 ↗ |
| Action | Inhibit | “S095035 is an oral methionine adenosyltransferase 2A [MAT2A] inhibitor.” NCT06188702 ↗ |
| Route | Oral | “S095035 will be taken orally every day in 28-day cycles.” NCT06188702 ↗ |
| Target | MAT2A | “S095035 is an oral methionine adenosyltransferase 2A [MAT2A] inhibitor.” NCT06188702 ↗ |